Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clazosentan phase 3 study in aneurysmal subarachnoid hemorrhage treated by surgical clipping
2007-002584-27Phase 3Completed
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Sep 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in subarachnoid hemorrhage (SAH) comparing Clazosentan with Placebo (2 arms). Primary endpoint: Cerebral vasospasm-related morbidity and all-cause mortality within 6 weeks post-aSAH. Started Sep 2007; status: completed.
02
Drugs
clazosentan
03
Conditions
subarachnoid hemorrhage (SAH)
Beyond the preview
Go deeper on 2007-002584-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-002584-27.